Gelteq is trading at $0.47, up +5.37%, with biotech strength the clearest available context; no company-specific catalyst is confirmed. - The biotech sector is up 2.18%, supported by positive clinical-trial and regulatory news; there is no evidence directly linking that broader news flow to Gelteq’s October 27 move. - Available news listings show no new catalyst for the October 27 rise. - The delayed 20-F filing is prior context, not a confirmed explanation for the gain.